Q4 Earnings Estimate for Chemours Issued By Zacks Research

The Chemours Company (NYSE:CC - Free Report) - Equities researchers at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for Chemours in a research note issued to investors on Wednesday, July 9th. Zacks Research analyst R. Department now forecasts that the specialty chemicals company will earn $0.30 per share for the quarter, down from their previous forecast of $0.34. The consensus estimate for Chemours' current full-year earnings is $2.03 per share.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a net margin of 0.54% and a return on equity of 23.82%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the company earned $0.32 earnings per share. The business's revenue was up .4% on a year-over-year basis.

Other analysts have also recently issued reports about the company. Wall Street Zen cut Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Truist Financial cut their price target on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Barclays cut their price target on Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 28th. Morgan Stanley cut their price target on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Finally, Mizuho set a $15.00 price target on Chemours in a report on Tuesday, April 15th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $17.33.

Chemours Trading Down 2.5%

CC stock traded down $0.35 during trading on Friday, hitting $13.48. The company had a trading volume of 2,977,001 shares, compared to its average volume of 3,455,344. The business has a 50-day moving average of $11.38 and a 200-day moving average of $13.91. Chemours has a one year low of $9.13 and a one year high of $25.54. The stock has a market cap of $2.02 billion, a PE ratio of 67.38 and a beta of 1.65. The company has a current ratio of 1.75, a quick ratio of 0.83 and a debt-to-equity ratio of 7.01.

Hedge Funds Weigh In On Chemours

A number of large investors have recently modified their holdings of CC. Charles Schwab Investment Management Inc. raised its position in Chemours by 6.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,302,272 shares of the specialty chemicals company's stock valued at $22,008,000 after buying an additional 73,220 shares during the last quarter. Victory Capital Management Inc. raised its position in Chemours by 6.8% in the 4th quarter. Victory Capital Management Inc. now owns 110,311 shares of the specialty chemicals company's stock valued at $1,864,000 after buying an additional 7,052 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in Chemours in the 4th quarter valued at $334,000. Raymond James Financial Inc. purchased a new stake in Chemours in the 4th quarter valued at $2,283,000. Finally, Swiss National Bank raised its position in Chemours by 1.0% in the 4th quarter. Swiss National Bank now owns 293,500 shares of the specialty chemicals company's stock valued at $4,960,000 after buying an additional 2,800 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Damian Gumpel bought 13,400 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were bought at an average cost of $9.22 per share, for a total transaction of $123,548.00. Following the acquisition, the insider directly owned 123,879 shares in the company, valued at approximately $1,142,164.38. This trade represents a 12.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Shane Hostetter bought 4,450 shares of the business's stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the completion of the acquisition, the chief financial officer owned 59,694 shares in the company, valued at $673,348.32. This represents a 8.06% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 25,672 shares of company stock worth $251,573. 0.34% of the stock is owned by company insiders.

Chemours Dividend Announcement

The company also recently announced a dividend, which was paid on Monday, June 16th. Investors of record on Monday, May 19th were issued a $0.0875 dividend. This represents a dividend yield of 3.17%. The ex-dividend date was Friday, May 16th. Chemours's dividend payout ratio is currently 175.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.